Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenmai Zhisou Inhalation Solution is a traditional Chinese medicine (TCM) candidate developed by Beijing Yingkerei Pharmaceutical Technology for the treatment of cough and other respiratory diseases. It is formulated as a solution for nebulized inhalation, a delivery method intended to provide direct action on the respiratory tract. The drug is currently in the preclinical stage of development. As a TCM formulation, its mechanism likely involves a multi-target approach characteristic of herbal medicine, though specific molecular targets are not defined in the provided pipeline information. The name 'Shenmai' typically refers to the inclusion of ingredients like Ginseng (Ren Shen) and Ophiopogon (Mai Dong), which are traditionally used in Chinese medicine to nourish the lungs and relieve cough.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenmai Zhisou Inhalation Solution.